Brain Health Study Interviews
Principal Investigator: Leah Hanson, PhD, Rebecca Rossom, MD, MS
Study sponsor: National Institutes of Health
Purpose of study: The Brain Health Study is conducting interviews to learn more about the care experience of people who have been recently evaluated for concerns of memory loss and have a family member or partner helping with their care.
If you have received an invitation and would like to participate, please contact the Brain Health Study interview team:
952-967-6875
BrainHealthStudy@HealthPartners.org
Virtual Reality Cognitive Therapy for Alzheimer’s Disease
Principal Investigator: Leah Hanson, PhD
Study sponsor: Clarity Tek
Location: Center for Memory and Aging, Neuroscience Center
Purpose of study:Alzheimer’s disease (AD) and Alzheimer’s disease-related Dementias (ADRD) resulting in cognitive decline affects more than 5.8 million Americans. Given the impact of AD/ADRD on people’s quality of life, there is a great need for therapies focused on cognition. In this study we will test the feasibility, usability, and acceptability of a novel Virtual Reality Cognitive Therapy (VRCT) developed by ClarityTek, Inc. The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled. Participants and their care partners will utilize the VRCT within their home for 30 minutes, 3 times per week, for seven weeks.
Inclusion Criteria:
– Ability to provide and provision of signed and dated informed consent form
– Age 30-89
– Diagnosis of mild cognitive impairment (MCI), probably Alzheimer’s Disease (AD), or Alzheimer’s disease Related Dementias (ADRD)
– Montreal Cognitive Assessment (MoCA) score of 11-25
Exclusion Criteria:
– Non-English speaking
– History of seizure disorder, vertigo disorder, or severe motion sickness
– Severe visual/hearing impairment, aphasia, or facial injury
– Unwilling to participate in all study related activities
– History of any other serious condition that may limit their ability to participate in the intervention, as determined by the investigator
Study Contact:
Clinical Trials office
(651) 495-6363
ClinicalTrials@HealthPartners.com
For more information, please visit the study’s clinicaltrials.gov site at: https://clinicaltrials.gov/study/NCT05788848
